Therapeutic Drug Monitoring Market Size, Share Report, Analysis, Trends, Growth 2030

Therapeutic Drug Monitoring Market

Therapeutic Drug Monitoring Market by Product Split (Consumables, Equipment, Immunoassay Analyzers, Chromatography & MS Detectors , Clinical Chemistry Analyzers), By Technology Split (Immunoassays., Chemiluminescence Immunoassays, Colorimetric Immunoassays, Fluorescence Immunoassays, Radioimmunoassays, Other Immunoassays, Chromatography-MS, LC-MS, GC-MS), By Class of drug Split (Antiepileptic Drugs, Antibiotic Drugs, Immunosuppressant Drugs, Antiarrhythmic Drugs, Bronchodilator Drugs, Psychoactive Drugs, Other Drugs), By End User Split (Hospital Laboratories, Commercial & Private Laboratories, Other End Users) and By Region – Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data and Forecasts 2021 – 2028

Category: Healthcare Report Format : PDF Pages: 188 Report Code: ZMR-3497 Published Date: May-2022 Status : Published

Global Therapeutic Drug Monitoring market was worth $1,692.9 billion in 2021 and is expected to reach $2854.83 billion by 2028, growing at a CAGR of 9.10%.

Therapeutic Drug Monitoring Market

Industry Prospective:

The global Therapeutic Drug Monitoring market was worth around USD 1,692.90 billion in 2021 and is estimated to grow to about USD 2854.83 billion by 2028, with a compound annual growth rate (CAGR) of approximately 9.10 percent over the forecast period. The report analyzes the Therapeutic Drug Monitoring market’s drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the Therapeutic Drug Monitoring market.

Therapeutic Drug Monitoring Market: Overview

Therapeutic drug monitoring is a test that involves measuring different medications in the bloodstream to ensure that the correct amount of treatment is being provided. It determines whether the quantity is sufficient to be useful while avoiding any serious reactions or adverse effects. Anti-arrhythmics, antibiotics, anti-epileptics, and psychotropic medications all require monitoring to guarantee their safety and effectiveness.

 One of the primary factors driving the market's growth is the increase in demand for hospitals and medical care facilities around the world.The growing importance of (TDM) in organ transplant procedures, as well as a growing inclination for precision medicine, are propelling the market forward. The market is also influenced by the increased focus on drug research and development activities, as well as the widespread use of drug monitoring tests across many therapeutic disciplines.

COVID-19 Impact:

Globally, COVID-19 has had a global impact on the pharmaceutical, diagnostics and medical industries, especially the therapeutic drug monitoring sector.Closed manufacturing facilities impacted supply chains and limited recruitment; nonetheless, restarting clinical trials in the COVID-19 pandemic recovery phase 2021 will be difficult because to restricted access at trial sites. As a result, any further delays in clinical trials will have an impact on the overall therapeutic drug monitoring market's growth in 2021. As a result of the sick population, medical supplies are in higher demand. Respiratory support equipment, such as an atomizer, a life-support machine, an oxygen generator, and a monitor, are among the most regularly utilised medical devices in primary clinical care. The need for medical supplies from both healthcare professionals and the general population is increasing as the number of COVID-19 cases increases around the world. By keeping a consistent supply of personal protective equipment on the market, manufacturers of these items can profit from the increased demand for medical supplies.

Global Therapeutic Drug Monitoring Market Request Free Sample

Therapeutic Drug Monitoring Market: Growth Drivers

Increasing preference for precision medicine of the market growth

 Precision medicine is a growing field of disease treatment and prevention that takes into account individual differences in genes, surroundings, and lifestyles. Precision medicine is picking treatments that are completely suited to a patient's ailment and medical history. Oncology has experienced the most development, despite the fact that this technique is extending into all disease areas. Cancer patients are being treated with a combination of medications based on studies of the patient's factors such as systems biology, tumour analysis, and gene expression data in the absence and presence of pharmacological disruption. This method, which is now being tried in a variety of situations, intends to transform pharmacotherapy in oncology and other disease areas. TDM has the potential to make a significant contribution to the advancement of this unique approach to patient care.

Therapeutic Drug Monitoring Market: Restraints

 Operational barriers faced in conducting TDM tests of the market growth

Clinical laboratories across major markets are still changing. As a result, technicians have operational issues in procuring, storing, and transporting samples, particularly when using novel technologies like chemiluminescence immunoassays, HPLC, and multiplex flow immunoassays (MFI). To eliminate cross-contamination and maintain efficient time management, laboratory space must also be redesigned to match the requirements of conducting specialised immunoassay tests for pathogen identification. The cost of maintaining and operating modern immunoassay devices, especially those that can only handle a single sample type, is prohibitive..

Therapeutic Drug Monitoring Market: Opportunities

Increasing adoption in the treatment of autoimmune diseases of the market growth

 Anti-TNF-alpha biologics are used to treat autoimmune illnesses such rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) (IBD). The number of R&D initiatives focusing on the creation of biosimilars has expanded in recent years as healthcare expenses have risen and patents have expired. With the introduction of biosimilars to the market, there is a greater need to evaluate potential changes in biosimilar immunogenicity, as well as their safety and effectiveness characteristics when compared to their predecessors. TNF-alpha blockers like infliximab and adalimumab, for example, can both elicit immunogenicity reactions; researchers have speculated that their biosimilars medicines (CT-P13) may do the same. To provide optimal patient care, it is critical to develop methodologies for the TDM of biosimilar medications for autoimmune disorders..

Global Therapeutic Drug Monitoring Market: Segmentation

The global Therapeutic Drug Monitoring market is segregated based on product split, technology split, glass of drug split,end user split , and region.

The Therapeutic Drug Monitoring market is divided into Consumables, Equipment-Immunoassay Analyzers, Chromatography & MS Detectors, and Clinical Chemistry Analyzers based on the type of product. During the period of 2021 to 2028, the Consumables segment is expected to grow at the fastest CAGR. The demand for recurring purchases of kits and reagents, as well as the growing number of immunoassay tests performed around the world, are two important reasons driving the growth of this market..

By end user split, the market is divided into Hospital Laboratories, Commercial & Private Laboratories and Other End Users). Hospital Laboratories is having the largest share for the end uer split. Personalized medicine is propelling the therapeutic drug monitoring market forward, owing to rising desire for improved treatment outcomes with fewer medication side effects. TDM, for example, is widely used for anti-cancer drug monitoring, for which various oncology journals and societies, including the European Journal of Oncology, have published standard standards. Advanced treatment techniques such as pharmacogenomics, gene testing, and proteomics are also projected to drive market expansion. One of the primary factors driving the TDM market's growth is the rise of antimicrobial resistance.

Report Scope:

 

Recent Developments

  • June 2021 - Implementing a personalised therapeutic drug monitoring (TDM) strategy at the time of infliximab beginning does not increase remission rates in patients with a variety of inflammatory disorders, according to study results presented at the EULAR 2020 E-Congress.
  • February 2019 - LabCorp, a prominent global life sciences firm, recently announced the addition of a new assay to its DoseASSURE therapeutic drug monitoring (TDM) platform. The novel Certolizumab Concentration and Anti-Certolizumab Antibody DoseASSURE CTZ assay aids physicians in tracking individual treatment response in patients taking Certolizumab, a biologic therapy used to treat inflammatory illnesses like rheumatoid arthritis and Crohn's disease.

Regional Landscape

North America is having the largest share because of its superior health care base, strong regional economies, and government emphasis on prevention and wellness. Increased per capita healthcare expenditures and the development of technologically advanced healthcare infrastructure are driving this industry forward. Furthermore, the region's focus has changed away from simple TDM tests and toward comprehensive testing in order to identify the gaps between prescribing the correct drug dosage and attaining the intended therapeutic outcome.

Competitive Landscape

Some of the main competitors dominating the global Therapeutic Drug Monitoring market include - Abbott (US), Thermo Fisher Scientific (US), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), Danaher Corporation (US), Bio-Rad Laboratories (US), bioMérieux SA (France), Theradiag SA (France), Grifols S.A. (Spain), Exagen Inc. (US), R-Biopharm AG (Germany), ApDia Group (Belgium), UTAK (US), Randox Laboratories Ltd. (Ireland), ARK Diagnostics, Inc. (US). BioTeZ Berlin-Buch GmbH (Germany), Eagle Biosciences, Inc. (US), Jasem Laboratory Systems and Solutions (Turkey), Aalto Scientific, Ltd. (US), Immundiagnostik AG (Germany), Sekisui Medical Co. Ltd. (Japan), DiaSystem Scandinavia AB (Sweden), Cambridge Life Sciences Limited (UK), Chromsystems Instruments & Chemicals GmbH (Germany), and BÜHLMANN Laboratories (Switzerland).

Global Therapeutic Drug Monitoring market is segmented as follows:

By Product Split

  • Consumables
  • Equipment
  • Immunoassay Analyzers
  • Chromatography & MS Detectors
  • Clinical Chemistry Analyzers

By Technology Split

  • Immunoassays.
  • Chemiluminescence Immunoassays
  • Colorimetric Immunoassays
  • Fluorescence Immunoassays
  • Radioimmunoassays
  • Other Immunoassays
  • Chromatography-MS
  • LC-MS
  • GC-MS

By Class of drug Split

  • Antiepileptic Drugs
  • Antibiotic Drugs
  • Immunosuppressant Drugs
  • Antiarrhythmic Drugs
  • Bronchodilator Drugs
  • Psychoactive Drugs
  • Other Drugs

By End user Split

  • Hospital Laboratories
  • Commercial & Private Laboratories
  • Other End Users

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France 
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

Methodology

Free Analysis

FrequentlyAsked Questions

The therapeutic drug monitoring market is predicted to develop due to factors such as an increase in demand for better healthcare in the urban population, an increase in the number of organ transplant surgeries, and the use of therapeutic drug monitoring in traditional anticancer therapy.

According to the Market Research report, the global Therapeutic Drug Monitoring market was worth about 1692.90 (USD billion) in 2021 and is predicted to grow to around 2854.83 (USD billion) by 2028, with a compound annual growth rate (CAGR) of around 9.10 percent.

North America leads the global Therapeutic Drug Monitoring because of the region's technologically advanced healthcare infrastructure. Due to increased investments in the region, Asia-Pacific (APAC) is predicted to develop significantly during the forecast period of 2022 to 2029.

Some of the main competitors dominating the global Therapeutic Drug Monitoring market include - Abbott (US), Thermo Fisher Scientific (US), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), Danaher Corporation (US), Bio-Rad Laboratories (US), bioMérieux SA (France), Theradiag SA (France), Grifols S.A. (Spain), Exagen Inc. (US), R-Biopharm AG (Germany), ApDia Group (Belgium), UTAK (US), Randox Laboratories Ltd. (Ireland), ARK Diagnostics, Inc. (US). BioTeZ Berlin-Buch GmbH (Germany), Eagle Biosciences, Inc. (US), Jasem Laboratory Systems and Solutions (Turkey), Aalto Scientific, Ltd. (US), Immundiagnostik AG (Germany), Sekisui Medical Co. Ltd. (Japan), DiaSystem Scandinavia AB (Sweden), Cambridge Life Sciences Limited (UK), Chromsystems Instruments & Chemicals GmbH (Germany), and BÜHLMANN Laboratories (Switzerland).

Choose License Type

  • zion payment modes

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008

Contact #

US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Industry Press Release

We Accept

We have secured system to process your transaction.

  • payment methods

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed